Matrix Metalloproteinases, Tissue Inhibitors of Metalloproteinases, and Their Ratios in Women with Polycystic Ovary Syndrome and Healthy Controls
International Journal of Molecular Sciences · 01.01.2025 · 26 (1) · 321
DOI: 10.3390/ijms26010321 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 01.01.2025. Verfasst von Alexandra E Butler und 4 weiteren Autor:innen. Beteiligte Einrichtung: Research Department, Royal College of Surgeons of Ireland, Adliya 15503, Bahrain. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Matrix Metalloproteinases, Tissue Inhibitor of Metalloproteinases. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Matrix metalloproteinases (MMPs) are M2 macrophage markers that are modulated by inflammation. A disintegrin and metalloproteinases (ADAMS) and those with thrombospondin motifs (ADAMTS) regulate the shedding of membrane-bound proteins, growth factors, cytokines, ligands, and receptors; MMPs, ADAMS, and ADAMTS may be regulated by tissue inhibitors of metalloproteinases (TIMPs). This study aimed to determine whether these interacting proteins were dysregulated in PCOS. A Somascan proteomic analysis of 12 MMPs, three of their inhibitors (TIMP-1, 2, 3), two ADAMS (9, 12), five ADAMTS (1, 4, 5, 13, 15), insulin-like growth factor binding protein-1 (IGFBP-1), and insulin-like growth factor-1 (IGF-1) was undertaken in a well-validated PCOS database of 143 women with PCOS and 97 controls. Women with PCOS had significantly higher levels of MMP-9 and lower levels of MMP-2, MMP-14, TIMP-2, IGFBP-1, and IGF-1 compared to the controls (p < 0.0001, p < 0.005, p < 0.04, p < 0.05, p < 0.0001, and p < 0.0001, respectively). No differences were observed for any other MMPs. The ADAMS or ADAMTS levels did not differ between groups. Body mass index (BMI) was correlated with MMP-9 (p < 0.01), MMP-1 (p < 0.05), MMP-2 (p < 0.05), MMP-10 (p < 0.005), MMP-12 (p < 0.005), ADAM-9 (p < 0.05), and IGFBP-1 (p < 0.0001), but only MMP-9 still differed after accounting for BMI. MMP-9/TIMP-1, MMP-9/TIMP-2, and MMP-9/TIMP-3 ratios were higher in the PCOS group (p < 0.01), whilst MMP-17/TIMP-1 and MMP-17/TIMP-2 were lower (p = 0.01). MMP-2/TIMP ratios showed no difference between groups. TIMP-2 was positively correlated with CRP (p < 0.01). MMP changes in PCOS are largely driven by BMI, though increased MMP-9 is BMI-independent, suggesting that any deleterious effects of MMP-9 would be potentially exacerbated by a concomitantly increased BMI. The significant increases in the MMP-9/TIMP ratios suggests MMP-9 overactivity in PCOS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Department, Royal College of Surgeons of Ireland, Adliya 15503, Bahrain.
- Academic Endocrinology, Diabetes and Metabolism, Hull York Medical School, Hull HU6 7RX, UK.
ORCID-Profile: Alexandra E Butler, Thozhukat Sathyapalan, Edwina Brennan, Stephen L Atkin
Zitieren
APA
Butler, A. E., Nandakumar, M., Sathyapalan, T., Brennan, E., & Atkin, S. L. (2025). Matrix Metalloproteinases, Tissue Inhibitors of Metalloproteinases, and Their Ratios in Women with Polycystic Ovary Syndrome and Healthy Controls. International Journal of Molecular Sciences, 26(1), 321. https://doi.org/10.3390/ijms26010321
Vancouver
Butler AE, Nandakumar M, Sathyapalan T, Brennan E, Atkin SL. Matrix Metalloproteinases, Tissue Inhibitors of Metalloproteinases, and Their Ratios in Women with Polycystic Ovary Syndrome and Healthy Controls. International Journal of Molecular Sciences. 2025;26(1):321. doi:10.3390/ijms26010321
BibTeX
@article{Butler2025,
author = {Butler, Alexandra E and Nandakumar, Manjula and Sathyapalan, Thozhukat and Brennan, Edwina and Atkin, Stephen L},
title = {Matrix Metalloproteinases, Tissue Inhibitors of Metalloproteinases, and Their Ratios in Women with Polycystic Ovary Syndrome and Healthy Controls},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {1},
pages = {321},
doi = {10.3390/ijms26010321}
}
EUVIMED